Oximio Israel excels in securing import licenses for unlicensed medication
We are delighted to announce that Oximio Israel has been successfully awarded yet another import license for Compassionate use program in January 2023.
“Compassionate use” allows for a patient outside of clinical trials with a serious or life-threatening disease to gain access to an investigational medical product including drug, biologic, or medical device when no alternative therapy options are available.
There are three scenarios when a patient can get an access to the unlicensed medication:
- Compassionate use program: the patient has never taken part in a clinical trial.
- Post-trial access: the patient has completed or dropped out of the clinical trial.
- Unlicensed supply: when the unregistered medication can be imported for an individual patient.
Oximio Israel has been successfully arranging licences for the above programmes since 2014.
At Oximio we strive to put the patient first and to find solutions to better our patient-centric services to compassionately achieve the best experience and outcome for the person and the family.
